1. Kathawala F.G., Scallen T., Engstrom R.G., et al. (1988): XU 62–320, an HMG-CoA reductase inhibitor, more potent than compactin and lovastatin. Eighth International Symposium on Atherosclerosis, Rome, October 9–13, p. 445.
2. Kathawala F.G. (1991): HMG-CoA reductase inhibitors: an exciting development in the treatment of hyperlipoproteinemia. Med. Res. Rev., 11, 121–146.
3. Engstrom R.G., Weinstein D.B., Kathawala F.G., et al. (1988): Hypolipoproteinemic activity of XU 62–320, a potent competitive inhibitor of HMG-CoA reductase. Eighth International Symposium on Atherosclerosis. Rome, October 9–13, p. 445.
4. Blum C.B., Levy R.L.I. (1989): Current therapy for hypercholesterolemia. JAMA, 26, 3582–3587.
5. Illingworth D.R. (1990): Treatment of hyperlipidaemia. BMB, 46, 1025–1058.